Dapaglifozine, marketed under the name Forxiga®, is an anti-diabetic drug in the glifozin class. It is a SGLT-2 transporter inhibitor that reduces glycated hemoglobin, leads to weight loss and improves blood pressure in patients with type 2 diabetes. Dapaglifozine may be given alone or in combination with insulin, an antihyperglycemic agent, depending on the degree of diabetes.

Since the start of the Covid-19 pandemic, physicians have observed that some patients are at increased risk of developing serious complications that could lead to death. One of the factors that may increase this risk are cardiometabolic diseases such as hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and heart and kidney failure. Since inhibitors of SGLT-2 transporters have shown strong protective effects on the heart and kidneys in patients with type 2 diabetes, dapaglifozine could protect these vital organ systems in Covid-19.